Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

E-therapeutics Adds New Board Member

This article was originally published in Scrip

Executive Summary

E-Therapeutics PLC. has appointed Trevor Mervyn Jones as non-executive director. Rajesh Chopra will be resigning as non-executive director to return to academic research. Currently Jones is chair of the international clinical research organisation (CRO), Simbec-Orion Group Ltd. and Welsh investment company, Arthurian Life Sciences Ltd. Previously he was director of Allergan Inc. and R&D director of The Wellcome Foundation and has also held advisory and regulatory roles. He was director general of the Association of the British Pharmaceutical Industry (ABPI), board member of the European Federation of Pharmaceutical Industry Associations (EFPIA) and the International Federation of Pharmaceutical Manufacturers Associations (IFPMA). Jones was also a member of the UK government regulatory agency, The Medicines Commission for 12 years.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC030186

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel